The Effects of Pharmacological Urate-Lowering Therapy on Cardiovascular Disease in Older Adults with Gout

Area of Science:

• Gerontology
• Rheumatology
• Cardiology

Background:

• Cardiovascular disease (CVD) is a leading cause of mortality in older adults.
• Hyperuricemia and gout are increasingly prevalent in older populations, elevating CVD risk.
• Gout patients exhibit higher CVD morbidity and mortality due to risk factors and inflammation.

Purpose of the Study:

• To highlight the importance of cardiovascular risk management in older adults with gout.
• To discuss the role of hyperuricemia and gout in cardiovascular health.
• To review current risk management strategies and identify evidence gaps.

Main Methods:

• Literature review and synthesis of existing research on gout, hyperuricemia, and cardiovascular disease in older adults.
• Analysis of the interplay between traditional cardiovascular risk factors, gout, and hyperuricemia.
• Evaluation of the evidence for urate-lowering therapy in reducing cardiovascular events.

Main Results:

• Older adults with gout have increased cardiovascular risk from traditional factors and gout's inflammatory burden.
• Urate-lowering therapy's efficacy in reducing cardiovascular events lacks sufficient evidence.
• No specific urate-lowering drug shows cardiovascular preference in gout patients.

Conclusions:

• Personalized treatment for older gout patients should optimize serum uric acid and manage traditional cardiovascular risk factors.
• Further prospective randomized trials are essential to validate urate-lowering therapy's cardiovascular benefits in this population.
• Comprehensive cardiovascular risk management is crucial for older adults with gout.